Stock listing
Frankfurt:AP82 Aptevo Therapeutics Inc. Aktie
German listing (Frankfurt) of Aptevo Therapeutics Inc. · home listing NASDAQ:APVO
Follow Aptevo Therapeutics Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:APVO
$0.404 USD -0.042 (-9.4%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:APVO
- Day range
- $0.394 – $0.425 USDNov 20, 2026
- Volume
- 148,733 sharesNov 20, 2026
- Market cap
- $1.40M USDAt the close on Nov 20, 2026 · price × 3.46M shares outstanding
- 52-week range
- $0.394 – $25.560 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $194,871 USDMedian day 42,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:APVO · Home | $0.404 USD | -0.042 (-9.4%) | 148,733 | $0.415 | $0.425 | $0.394 | $0.446 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:APVO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.404 | -0.042 | -9.4% | $0.415 | $0.425 | $0.394 | 148,733 | |
| $0.446 | -0.015 | -3.3% | $0.470 | $0.470 | $0.422 | 627,299 | |
| $0.461 | -0.088 | -16.0% | $0.540 | $0.550 | $0.450 | 138,059 | |
| $0.549 | -0.045 | -7.7% | $0.600 | $0.606 | $0.546 | 163,744 | |
| $0.594 | -0.066 | -10.0% | $0.665 | $0.670 | $0.594 | 109,554 | |
| $0.660 | -0.100 | -13.1% | $0.770 | $0.770 | $0.650 | 227,148 | |
| $0.760 | -0.320 | -29.6% | $0.787 | $0.830 | $0.740 | 610,953 | |
| $1.080 | -0.050 | -4.4% | $1.140 | $1.140 | $1.070 | 50,530 | |
| $1.130 | -0.110 | -8.9% | $1.190 | $1.220 | $1.090 | 74,299 | |
| $1.240 | -0.030 | -2.4% | $1.300 | $1.323 | $1.200 | 32,800 | |
| $1.270 | -0.100 | -7.3% | $1.370 | $1.370 | $1.070 | 144,100 | |
| $1.370 | +0.010 | +0.7% | $1.345 | $1.380 | $1.310 | 14,800 | |
| $1.360 | +0.010 | +0.7% | $1.440 | $1.440 | $1.310 | 14,000 | |
| $1.350 | +0.010 | +0.7% | $1.393 | $1.398 | $1.329 | 23,000 | |
| $1.340 | -0.020 | -1.5% | $1.360 | $1.386 | $1.310 | 28,700 | |
| $1.360 | +0.060 | +4.6% | $1.320 | $1.410 | $1.310 | 58,500 | |
| $1.300 | +0.020 | +1.6% | $1.360 | $1.370 | $1.260 | 42,200 | |
| $1.280 | -0.220 | -14.7% | $1.550 | $1.580 | $1.253 | 80,600 | |
| $1.500 | -0.110 | -6.8% | $1.740 | $1.740 | $1.430 | 123,700 | |
| $1.610 | 0.000 | 0.0% | $1.610 | $1.636 | $1.600 | 7,200 | |
| $1.610 | +0.010 | +0.6% | $1.605 | $1.640 | $1.600 | 5,300 | |
| $1.600 | -0.015 | -0.9% | $1.630 | $1.650 | $1.600 | 8,600 | |
| $1.615 | +0.015 | +0.9% | $1.600 | $1.650 | $1.600 | 12,600 | |
| $1.600 | -0.020 | -1.2% | $1.655 | $1.655 | $1.568 | 8,400 | |
| $1.620 | -0.080 | -4.7% | $1.730 | $1.730 | $1.600 | 31,100 | |
| $1.700 | -0.030 | -1.7% | $1.730 | $1.740 | $1.700 | 10,800 | |
| $1.730 | 0.000 | 0.0% | $1.730 | $1.780 | $1.710 | 21,900 | |
| $1.730 | -0.106 | -5.8% | $1.790 | $1.790 | $1.700 | 85,700 | |
| $1.836 | +0.046 | +2.6% | $1.790 | $1.970 | $1.760 | 282,300 | |
| $1.790 | -0.010 | -0.6% | $1.790 | $1.810 | $1.780 | 6,700 | |
| $1.800 | -0.040 | -2.2% | $1.770 | $1.840 | $1.770 | 26,700 | |
| $1.840 | +0.045 | +2.5% | $1.760 | $1.850 | $1.760 | 12,100 | |
| $1.795 | -0.005 | -0.3% | $1.820 | $1.920 | $1.790 | 35,400 | |
| $1.800 | +0.040 | +2.3% | $1.760 | $1.850 | $1.750 | 28,100 | |
| $1.760 | 0.000 | 0.0% | $1.800 | $1.800 | $1.760 | 12,600 | |
| $1.760 | -0.060 | -3.3% | $1.820 | $1.840 | $1.750 | 25,000 | |
| $1.820 | -0.040 | -2.2% | $1.840 | $1.900 | $1.810 | 24,100 | |
| $1.860 | -0.050 | -2.6% | $1.900 | $1.910 | $1.840 | 15,000 | |
| $1.910 | +0.020 | +1.1% | $1.860 | $1.980 | $1.860 | 47,000 | |
| $1.890 | +0.060 | +3.3% | $1.830 | $1.900 | $1.818 | 25,500 | |
| $1.830 | -0.060 | -3.2% | $1.880 | $1.900 | $1.810 | 33,000 | |
| $1.890 | +0.040 | +2.2% | $1.880 | $1.895 | $1.800 | 53,300 | |
| $1.850 | +0.040 | +2.2% | $1.814 | $1.890 | $1.814 | 39,200 | |
| $1.810 | -0.030 | -1.6% | $1.842 | $1.890 | $1.805 | 22,400 | |
| $1.840 | 0.000 | 0.0% | $1.850 | $1.890 | $1.820 | 40,800 | |
| $1.840 | +0.120 | +7.0% | $1.790 | $1.900 | $1.730 | 423,800 | |
| $1.720 | +0.010 | +0.6% | $1.711 | $1.800 | $1.711 | 54,000 | |
| $1.710 | -0.090 | -5.0% | $1.810 | $1.840 | $1.710 | 48,300 | |
| $1.800 | -0.020 | -1.1% | $1.854 | $1.895 | $1.800 | 46,100 | |
| $1.820 | -0.010 | -0.5% | $1.830 | $1.920 | $1.800 | 43,600 | |
| $1.830 | -0.015 | -0.8% | $1.820 | $1.880 | $1.760 | 56,500 | |
| $1.845 | -0.035 | -1.9% | $1.890 | $1.990 | $1.820 | 43,900 | |
| $1.880 | +0.140 | +8.0% | $1.770 | $1.930 | $1.745 | 168,100 | |
| $1.740 | +0.030 | +1.8% | $1.740 | $1.796 | $1.640 | 272,100 | |
| $1.710 | -0.890 | -34.2% | $2.110 | $2.180 | $1.370 | 1,689,600 | |
| $2.600 | +0.260 | +11.1% | $2.340 | $2.770 | $2.330 | 1,027,600 | |
| $2.340 | -0.100 | -4.1% | $2.440 | $2.440 | $2.340 | 32,000 | |
| $2.440 | +0.075 | +3.2% | $2.350 | $2.450 | $2.350 | 29,700 | |
| $2.365 | -0.055 | -2.3% | $2.460 | $2.460 | $2.310 | 21,500 | |
| $2.420 | +0.010 | +0.4% | $2.410 | $2.420 | $2.340 | 35,100 | |
| $2.410 | -0.050 | -2.0% | $2.490 | $2.550 | $2.410 | 27,600 | |
| $2.460 | +0.050 | +2.1% | $2.370 | $2.500 | $2.301 | 58,598 | |
| $2.410 | -0.270 | -10.1% | $2.760 | $2.760 | $2.380 | 194,986 | |
| $2.680 | -0.080 | -2.9% | $2.840 | $2.850 | $2.580 | 54,100 | |
| $2.760 | +0.030 | +1.1% | $2.740 | $2.912 | $2.723 | 63,800 |
Splits
5 splits since 2020 · NASDAQ:APVO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-18 | Consolidation | |
| 1-for-20 | Consolidation | |
| 1-for-37 | Consolidation | |
| 1-for-44 | Consolidation | |
| 1-for-14 | Consolidation |
- Ticker
- Frankfurt:AP82
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
Latest news
Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
Nov 16, 2026
Closed $0.549 (-7.7%) on Nov 16, 2026
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross Proceeds
Nov 12, 2026
Closed $0.594 (-10.0%) on Nov 13, 2026
Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds
Nov 11, 2026
Closed $0.76 (-29.6%) on Nov 11, 2026
Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors
Nov 9, 2026
Closed $1.13 (-8.9%) on Nov 9, 2026
Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
Nov 5, 2026
Closed $1.27 (-7.3%) on Nov 5, 2026
Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
Oct 26, 2026
Closed $1.50 (-6.8%) on Oct 26, 2026
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
Oct 14, 2026
Closed $1.73 (0.0%) on Oct 14, 2026
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Sep 3, 2026
Closed $1.71 (-34.2%) on Sep 3, 2026
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
Aug 14, 2026
Closed $2.94 (-13.5%) on Aug 14, 2026
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
Aug 13, 2026
Closed $2.94 (-13.5%) on Aug 14, 2026
Aptevo Therapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 101 in all · newest Nov 16, 2026 · oldest 2019
- Decks
- 10 decks · latest Mar 20, 2025
Where Aptevo Therapeutics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:APVO · Home listing | NASDAQ | United States | USD |
| BOATS:APVO | BOATS | United States | USD |
| gettex:AP82 | gettex | Germany | EUR |
| Frankfurt:AP82 · This page | Frankfurt | Germany | EUR |
| Munich:AP82 | Munich | Germany | EUR |
Valuation
Price/book 0.4× against a median of 0.2×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$2.88M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 1.0×
- Beta vs S&P 500
- 0.93
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Aptevo Therapeutics Inc. · NASDAQ:APVO | US$1.40M | −US$2.88M | n/a | n/a | n/a | 0.4× | n/a | 1.0× | 0.93 |
| PRF Technologies Ltd. · NASDAQ:PRFX | US$1.66M | −US$9.82M | n/a | −249× | n/a | 0.1× | n/a | 0.0× | 1.93 |
| Jupiter Neurosciences, Inc. · NASDAQ:JUNS | US$1.63M | US$1.33M | n/a | 16.9× | n/a | n/a | n/a | n/a | 1.88 |
| Kairos Pharma, Ltd. · AMEX:KAPA | US$1.48M | −US$1.65M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.36 |
| BioRestorative Therapies, Inc. · NASDAQ:BRTX | US$1.45M | −US$2.11M | n/a | −5.9× | n/a | 0.5× | n/a | 0.0× | 1.81 |
| Nutra Pharma Corp. · OTC:NPHC | US$1.43M | US$13.99M | n/a | 87.0× | n/a | n/a | n/a | n/a | n/a |
| Agentix Corp. · OTC:AGTX | US$1.35M | US$1.34M | n/a | n/a | n/a | n/a | n/a | n/a | -0.73 |
| Clearmind Medicine Inc. · NASDAQ:CMND | US$1.33M | −US$9.01M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 0.29 |
| Artelo Biosciences, Inc. · NASDAQ:ARTL | US$1.30M | US$1.34M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 1.36 |
| International Stem Cell Corporation · OTC:ISCO | US$1.28M | −US$18.76M | 0.1× | −2.0× | n/a | 0.1× | 222.6% | 0.0× | -0.52 |
| SureNano Science Ltd · CSE:SURE | US$1.17M | US$672,321 | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.25 |
| Median of the others | US$1.39M | −US$488,496 | 0.1× | −2.0× | 0.2× | 222.6% | 0.0× | 1.36 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 25.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -16.02 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Jeff Lamothe | President and Chief Executive Officer |
| Daphne Taylor | Senior Vice President and Chief Financial Officer |
| Daniel J. Abdun-Nabi | President |
| SoYoung Kwon | Senior Vice President and General Counsel, Business Development and Corporate Affairs |
| Miriam Weber Miller | Vice President, Investor Relations and Corporate Communications |
| Dirk Huebner | Senior Vice President and Chief Medical Officer |
| Mary J. Janatpour | Senior Vice President and Chief Scientific Officer |
| Marvin L. White | Executive Chair |
Board
| Director | Role |
|---|---|
| Marvin L. White | Executive Chair |
| Jeff Lamothe | President and Chief Executive Officer |
| John E. Niederhuber | Lead Independent Director |
| Zsolt Harsanyi | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · Before open | −7.7% |
| Q2 2026 | Aug 14, 2026 · Before open | −13.5% |
| Q1 2026 | May 13, 2026 · After close | +0.7% |
| Q4 2025 | Mar 26, 2026 | −3.5% |
| Q3 2025 | Nov 6, 2025 · After close | 0.0% |
| Q2 2025 | Aug 11, 2025 · Before open | −4.9% |
| Q1 2025 | May 15, 2025 · After close | −3.0% |
| Q4 2024 | Feb 14, 2025 · Before open | −8.2% |
| Q3 2024 | Nov 7, 2024 · Before open | +19.8% |
| Q2 2024 | Aug 8, 2024 · Before open | +0.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · Before open | −11.6% |
| Q4 2023 | Mar 5, 2024 · Before open | −8.6% |
| Q3 2023 | Nov 14, 2023 · Before open | +6.8% |
| Q2 2023 | Aug 10, 2023 · Before open | −9.7% |
| Q1 2023 | May 11, 2023 · Before open | −2.3% |
| Q4 2022 | Mar 30, 2023 · Before open | +1.0% |
| Q3 2022 | Nov 10, 2022 · Before open | +2.5% |
| Q2 2022 | Aug 11, 2022 · Before open | −1.8% |
| Q1 2022 | May 12, 2022 · Before open | +11.3% |
| Q4 2021 | Mar 24, 2022 · Before open | +32.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2025) | Investor deck | 27 slides | Mar 20, 2025 |
| Investor Presentation (February 2025) | Investor deck | 30 slides | Feb 11, 2025 |
| Investor Presentation (January 2019) | Investor deck | 31 slides | Jan 9, 2019 |
| Investor Presentation (January 2018) | Investor deck | 38 slides | Jan 8, 2018 |
| Investor Presentation (November 2017) | Investor deck | 38 slides | Nov 9, 2017 |
| Investor Presentation (November 2017) | Investor deck | 30 slides | Nov 2, 2017 |
| BIO International Convention 2017 | Conference | 53 slides | Jun 20, 2017 |
| Investor Presentation (January 2017) | Investor deck | 30 slides | Jan 9, 2017 |
| Investor Presentation (November 2016) | Investor deck | 30 slides | Nov 28, 2016 |
| Investor Presentation (August 2016) | Investor deck | 28 slides | Aug 8, 2016 |
Financings
| Raise | Date |
|---|---|
| Warrant exercise of common stock on exercise of existing warrants Closed: US$3M raised · US$1.08 a share · Warrants at US$1.08 for 60 months · Roth Capital Partners Dealers: Roth Capital Partners Use of proceeds: Working capital purposes | Nov 12, 2026 |
| Common stock on exercise of existing warrants Closed: US$4.03 a share · Warrants at US$4.03 for 60 months · Roth Capital Partners, LLC Dealers: Roth Capital Partners, LLC (lead) Use of proceeds: Working capital | Aug 13, 2026 |
| Private placement of unregistered shares of common stock (or pre-funded warrants) with common warrants Closed: US$4.03 a share · Warrants at US$4.03 for 60 months · Roth Capital Partners, LLC Dealers: Roth Capital Partners, LLC (lead) Use of proceeds: Working capital | Aug 13, 2026 |
| Shares under equity line of credit Announced: raise Buyers: Yorkville Advisors Global, LP (counterparty to $60 million equity line of credit; Aptevo may sell shares to it from time to time) Use of proceeds: Support ongoing clinical development, advance preclinical programs and fund general corporate purposes | Jan 9, 2026 |
| Registered direct offering of common stock or pre-funded warrants and common warrants Closed: US$8M raised · US$3.25 a share · Warrants at US$3.25 for 60 months · Roth Capital Partners Dealers: Roth Capital Partners (lead) Use of proceeds: Continued clinical development of product candidates, working capital and general corporate purposes | Jun 20, 2025 |
| Registered direct offering of common stock Closed: US$2M raised · US$0.862 a share · Roth Capital Partners Dealers: Roth Capital Partners (lead) Use of proceeds: Continued clinical development of product candidates, working capital and general corporate purposes | Apr 22, 2025 |
| Registered direct offering of common stock and warrants in concurrent private placement Closed: US$2.1M raised · US$1.19 a share · Warrants at US$1.19 for 60 months · Roth Capital Partners Dealers: Roth Capital Partners (lead) Use of proceeds: Continued clinical development of product candidates, working capital and general corporate purposes | Apr 4, 2025 |
| Warrant exercise of common stock upon exercise of existing warrants Announced: about US$6.2M · US$7.5 a share · Warrants at US$9.53 for 60 months · Roth Capital Partners Dealers: Roth Capital Partners Use of proceeds: Working capital and general corporate purposes | Dec 12, 2024 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 3.11M | 12.3M | 4.31M | 32.4M | 23.1M | 14.7M | 9.98M |
| Cost of revenue | 240.0K | 352.0K | 17.1M | 17.9M | 19.0M | 17.9M | 19.9M | 11.2M | 5.01M | 12.5M |
| Gross profit | -240.0K | -352.0K | -567.0K | 3.11M | 12.3M | -13.5M | -2.23M | 11.9M | 9.65M | 12.3M |
| Research and development | 14.5M | 14.4M | 17.1M | 17.9M | 19.0M | 17.9M | 24.8M | 35.4M | 29.0M | 29.1M |
| Selling, general and administrative | 11.8M | 10.2M | 11.8M | 13.9M | 14.7M | 14.0M | 25.3M | 28.1M | 34.6M | 36.2M |
| Operating income | -26.3M | -24.6M | -28.9M | -28.6M | -21.4M | -27.5M | -41.0M | -51.7M | -53.9M | -138.8M |
| Depreciation and amortization | 240.0K | 352.0K | 567.0K | 901.0K | 1.14M | 1.41M | 2.23M | 2.39M | 3.13M | 3.36M |
| EBITDA | -26.1M | -24.3M | -28.3M | -27.7M | -20.3M | -26.1M | -38.7M | -49.3M | -50.8M | -135.4M |
| Interest expense | 35.7M | 7.06M | 0 | 0 | 0 | 0 | 0 | |||
| Income before tax | -26.0M | -24.1M | -18.6M | 7.01M | -29.4M | -30.9M | -43.1M | -53.7M | -55.9M | -139.6M |
| Income tax | 0 | -1.24M | -35.7M | -2.10M | -12.5M | -2.62M | -23.3M | -23.3M | -19.7M | |
| Net income | -26.0M | -24.1M | -17.4M | 8.03M | -28.5M | -17.8M | -40.4M | -53.7M | 6.97M | -112.4M |
| Earnings per share, basic | -87.27 | -31,460.23 | -2,316.83 | 1.57 | -6.07 | -5.23 | -13.86 | -2.39 | 0.33 | -5.55 |
| Earnings per share, diluted | -87.27 | -31,460.23 | -2,316.83 | 1.57 | -6.07 | -5.23 | -13.86 | -2.39 | 0.33 | -5.55 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 21.6M | 8.71M | 16.9M | 22.6M | 45.0M | 40.0M | 12.4M | 30.6M | 7.09M | 9.68M |
| Short-term investments | 73.7M | 73.7M | 44.8M | |||||||
| Receivables | 2.50M | 3.66M | 2.37M | 7.02M | 5.22M | 2.14M | 307.0K | |||
| Inventory | 1.57M | 3.08M | 4.78M | 6.14M | 1.78M | 1.03M | 461.0K | |||
| Current assets | 23.1M | 10.7M | 19.1M | 27.4M | 52.6M | 47.3M | 30.0M | 48.7M | 95.1M | 71.4M |
| Property, plant and equipment | 303.0K | 543.0K | 895.0K | 1.46M | 2.38M | 2.81M | 3.95M | 5.20M | 5.84M | 5.91M |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 27.2M | 15.6M | 24.8M | 34.2M | 56.6M | 53.5M | 53.4M | 67.5M | 117.0M | 91.9M |
| Accounts payable | 877.0K | 1.24M | 3.98M | 3.50M | 3.46M | 5.58M | 6.43M | 11.7M | 7.35M | 10.5M |
| Current liabilities | 6.05M | 6.21M | 7.22M | 8.71M | 34.8M | 14.5M | 38.2M | 17.6M | 18.5M | 19.5M |
| Long-term debt | 1.46M | 3.71M | 20.1M | 19.3M | 15.7M | 18.4M | ||||
| Total debt | 4.63M | 4.63M | 0 | 4.01M | 16.0M | 28.2M | 19.9M | 19.3M | 19.1M | 18.4M |
| Total liabilities | 9.81M | 10.8M | 12.6M | 16.2M | 55.4M | 37.0M | 41.6M | 37.1M | 35.0M | 41.3M |
| Shareholders' equity | 17.4M | 4.75M | 12.2M | 18.0M | 1.22M | 16.6M | 11.8M | 30.4M | 82.0M | 50.6M |
| Shares outstanding | 997.8K | 4.05K | 12.0K | 6.47M | 4.90M | 4.41M | 3.23M | 22.8M | 21.6M | 20.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -25.6M | -23.8M | -11.7M | -21.0M | -21.7M | -29.3M | -42.4M | -51.4M | -41.6M | -36.9M |
| Capital spending | 0 | 0 | 0 | -29.0K | -713.0K | -88.0K | -153.0K | -976.0K | -1.40M | -2.51M |
| Free cash flow | -25.6M | -23.8M | -11.7M | -21.1M | -22.4M | -29.4M | -42.5M | -52.4M | -43.0M | -39.4M |
| Cash from investing | 0 | 0 | 0 | -29.0K | -713.0K | 28.0M | 4.10M | 72.8M | 29.5M | -47.4M |
| Cash from financing | 38.5M | 15.6M | 6.00M | -2.62M | 26.2M | 23.9M | 20.1M | -787.0K | 19.5M | 89.3M |
| Dividends paid | -1.57M | -4.00K | -10.2M | -21.2M | -58.0K | 0 | 0 | |||
| Share buybacks | -10.0K | -4.00K | 10.2M | -11.0K | -58.0K | -758.0K | -758.0K | 38.0K | ||
| Change in cash | 12.9M | -8.19M | -5.73M | -23.7M | 3.77M | 22.6M | -18.1M | 20.6M | 7.42M | 5.04M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-1 · Registration statement | Nov 20, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| PRE 14A · Preliminary proxy statement | Nov 13, 2026 | Meeting notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| 8-K · Current report | Nov 5, 2026 | Current report | SEC |
| 8-K · Current report | Oct 30, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 424B5 · Prospectus | Oct 30, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 26, 2026 | Current report | SEC |
| 8-K · Current report | Oct 23, 2026 | Material contract | SEC |
| 8-K · Current report | Oct 14, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Sep 25, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 24, 2026 | Current report | SEC |
| 8-K · Current report | Sep 23, 2026 | Meeting outcome | SEC |
| 424B4 · Prospectus | Sep 3, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 3, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 3, 2026 | Other filings | SEC |
| DEF 14A · Proxy statement | Aug 31, 2026 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Aug 31, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 27, 2026 | Other filings | SEC |
| D | Aug 26, 2026 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Aug 21, 2026 | Meeting notice | SEC |
| S-1 · Registration statement | Aug 21, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 21, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| 8-K · Current report | Aug 13, 2026 | Material contract | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| DEF 14A · Proxy statement | Jul 31, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Jul 31, 2026 | Annual report | SEC |
| 8-K · Current report | Jul 27, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jul 24, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 30, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 22, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jun 22, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 28, 2026 | Insider trade | SEC |
| 8-K · Current report | May 27, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| 8-K · Current report | May 6, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| 8-K · Current report | Mar 10, 2026 | Current report | SEC |
| 8-K · Current report | Feb 18, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 3, 2026 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Feb 2, 2026 | Other filings | SEC |
| 424B4 · Prospectus | Jan 30, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 29, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 29, 2026 | Other filings | SEC |
| S-1 · Registration statement | Jan 28, 2026 | Offer document | SEC |
| DEF 14A · Proxy statement | Jan 26, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jan 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jan 9, 2026 | Material contract | SEC |
| 8-K · Current report | Dec 29, 2025 | Current report | SEC |
| 8-K · Current report | Dec 9, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Nov 26, 2025 | Other filings | SEC |
| 424B4 · Prospectus | Nov 25, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Nov 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 8-K · Current report | Oct 30, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 3, 2025 | Insider trade | SEC |
| S-1 · Registration statement | Oct 1, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 16, 2025 | Current report | SEC |
| 8-K · Current report | Sep 4, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 8, 2025 | Insider trade | SEC |
| 424B4 · Prospectus | Aug 8, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 4, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 31, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 30, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jul 25, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 24, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jul 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 9, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 8, 2025 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Jul 7, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Jul 3, 2025 | Annual report | SEC |
| 8-K · Current report | Jul 1, 2025 | Current report | SEC |
| 8-K · Current report | Jun 30, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 25, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 25, 2025 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Jun 23, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 23, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 23, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 23, 2025 | Current report | SEC |
| 8-K · Current report | Jun 20, 2025 | Current report | SEC |
| 424B5 · Prospectus | Jun 20, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 20, 2025 | Material contract | SEC |
| 424B4 · Prospectus | Jun 20, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 20, 2025 | Other filings | SEC |
| S-1MEF · Registration of more shares for the same offering | Jun 18, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 17, 2025 | Material contract | SEC |
| CORRESP · Letter to the SEC | Jun 16, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jun 16, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 4, 2025 | Other filings | SEC |
| DRS · Draft registration statement | May 30, 2025 | Offer document | SEC |
| 424B3 · Prospectus | May 28, 2025 | Offer document | SEC |
| 8-K · Current report | May 23, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 23, 2025 | Other filings | SEC |
| 8-K · Current report | May 22, 2025 | Current report | SEC |
| 424B5 · Prospectus | May 22, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 21, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 20, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| S-1 · Registration statement | May 13, 2025 | Offer document | SEC |
| RW · Request to withdraw a registration | May 13, 2025 | Other filings | SEC |
| RW · Request to withdraw a registration | May 13, 2025 | Other filings | SEC |
| S-3 · Registration statement | May 2, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 29, 2025 | Current report | SEC |
| 424B5 · Prospectus | Apr 29, 2025 | Offer document | SEC |
| 424B4 · Prospectus | Apr 28, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 28, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 25, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 25, 2025 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 25, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 22, 2025 | Material contract | SEC |
| 424B4 · Prospectus | Apr 22, 2025 | Offer document | SEC |
| D | Apr 18, 2025 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Apr 10, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 9, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 4, 2025 | Material contract | SEC |
| 424B4 · Prospectus | Apr 4, 2025 | Offer document | SEC |
| S-1/A · Registration statement, amended | Apr 1, 2025 | Offer document | SEC |
| S-1/A · Registration statement, amended | Mar 27, 2025 | Offer document | SEC |
| S-1/A · Registration statement, amended | Mar 27, 2025 | Offer document | SEC |
| S-1/A · Registration statement, amended | Mar 25, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 20, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| S-1 · Registration statement | Mar 3, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 27, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 24, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 21, 2025 | Other filings | SEC |
| S-3 · Registration statement | Feb 14, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 14, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 14, 2025 | Results | SEC |
| 8-K · Current report | Feb 11, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jan 3, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 2, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 30, 2024 | Other filings | SEC |
| S-3 · Registration statement | Dec 20, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 12, 2024 | Material contract | SEC |
| 8-K · Current report | Dec 12, 2024 | Current report | SEC |
| 8-K · Current report | Dec 4, 2024 | Current report | SEC |
| 8-K · Current report | Dec 3, 2024 | Current report | SEC |
| 8-K · Current report | Nov 26, 2024 | Current report | SEC |
| 8-K · Current report | Nov 22, 2024 | Current report | SEC |
| 8-K · Current report | Nov 20, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
This page holds 200 of 748 filings. Open Filings
Cap table
Built by 6ix from Aptevo Therapeutics Inc.’s releases · as of Nov 16, 2026
- Common shares
- 3,464,923
- Fully diluted
- 3,464,923
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 3,464,923 | Nov 16, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.08 · expire about Nov 2031 |
| Warrants · US$4.03 · expire about Aug 2031 |
| Warrants · US$3.25 · expire about Jun 2030 |
| Warrants · US$1.19 · expire about Apr 2030 |
| Warrants · US$4.03 · expiry not stated |
| Warrants · US$1.08 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 16, 2026 | 3,464,923 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Anatolio B Cruz III Other companies: Graf Acquisition Corp IV (Director · May 20, 2021 – May 20, 2021 · Past); Scripps Networks Interactive Inc (CLO & Corporate Secretary · Jul 1, 2008 – Aug 14, 2012 · Past); E.W. Scripps Company (The) (EVP & General Counsel · Feb 15, 2006 – Jul 1, 2008 · Past) | Director · Jul 15, 2016 – Jul 15, 2016 · Past |
| Marvin L. White Other companies: Emergent BioSolutions Inc. (Independent Director · Since at least Jun 1, 2010); CoLucid Pharmaceuticals Inc (Director · Jul 9, 2015 – Mar 1, 2017 · Past); Washington Prime Group Inc (Director · May 8, 2014 – Aug 4, 2014 · Past) | Executive Chair · Since at least Jul 29, 2016 |
| Daniel J. Abdun-Nabi Other companies: Regenxbio Inc. (Director · Aug 5, 2016 – Jun 4, 2021 · Past); Emergent BioSolutions Inc. (CEO, Director · Nov 14, 2006 – Mar 4, 2019 · Past) | President · Since at least Aug 1, 2016 |
| Jane A. Gross Other companies: BriaCell Therapeutics Corp (Director of the Board · Since at least Aug 1, 2022); aTyr Pharma, Inc. (Director · Since at least Jun 28, 2019) | SVP & Chief Scientific Officer · Sep 1, 2016 – Jan 29, 2021 · Past |
| Shawnte M. Mitchell Other companies: Olema Pharmaceuticals, Inc. (Chief Legal Officer and Corporate Secretary · Since at least Feb 18, 2025); Zogenix Inc (EVP, GC & Secretary · Apr 20, 2020 – Mar 7, 2022 · Past) | SVP, GC and Corporate Affairs · Aug 1, 2018 – Feb 18, 2020 · Past |
| Dirk Huebner Other companies: Mersana Therapeutics Inc (Chief Medical Officer · Nov 30, 2018 – Jan 15, 2020 · Past) | Senior Vice President and Chief Medical Officer · Since at least Jul 1, 2025 |
| Fuad El-Hibri Other companies: Emergent BioSolutions Inc. (Director · Nov 14, 2006 – Dec 3, 2021 · Past) | Director · Aug 1, 2016 – Dec 3, 2021 · Past |
| John E. Niederhuber Other companies: Emergent BioSolutions Inc. (Director · Aug 23, 2010 – May 18, 2016 · Past) | Lead Independent Director · Since at least Aug 1, 2016 |
| Randy Joe Maddux Other companies: iBio, Inc. (Chief Operating Officer · Dec 1, 2020 – Dec 7, 2021 · Past) | SVP of Operations, CMO · Aug 23, 2016 – Jul 27, 2020 · Past |
| Robert Kramer Other companies: Emergent BioSolutions Inc. (President and CEO, Director · May 31, 2013 – Jun 9, 2023 · Past) | President, Director · Jul 15, 2016 – Jul 15, 2016 · Past |
All 23 people
| Person | Seat |
|---|---|
| Zsolt Harsanyi Other companies: Emergent BioSolutions Inc. (Independent Director, Chairman of the Board · Since at least Nov 14, 2006) | Director · Since at least Jul 15, 2016 |
| Barbara Lopez Kunz | Director · Since at least Aug 1, 2016 |
| Daphne Taylor | SVP, CFO · Since at least Mar 3, 2023 |
| Eric M Burt | Director · Jul 15, 2016 – Jul 15, 2016 · Past |
| Grady Grant III | Director · Since at least Aug 1, 2016 |
| Jeff Lamothe | President and Chief Executive Officer · Since at least Aug 10, 2026 |
| Jeffrey G Lamothe | President and CEO, Director · Since at least Jul 29, 2016 |
| Mary J. Janatpour | Senior Vice President and Chief Scientific Officer · Since at least May 20, 2026 |
| Michael Adelman | SVP, Commercial Operations · Nov 1, 2019 – Feb 18, 2020 · Past |
| Michael Darling | Director · Jul 15, 2016 – Jul 15, 2016 · Past |
| Miriam Weber Miller | Vice President, Investor Relations and Corporate Communications · Since at least Oct 26, 2026 |
| Scott C Stromatt | Chief Medical Officer and SVP · Jul 29, 2016 – Feb 28, 2019 · Past |
| SoYoung Kwon | Senior Vice President and General Counsel, Business Development and Corporate Affairs · Since at least May 24, 2021 |
Log in to ask 6ix AI your own questions about Aptevo Therapeutics Inc.